Merck and Co Inc v Arrow Pharmaceuticals Ltd

Link copied
Case Copied 5 min read

FEDERAL COURT OF AUSTRALIA

Merck & Co Inc v Arrow Pharmaceuticals Ltd [2005] FCA 425

APPEAL – practice and procedure – issue raised in notice of contention – no findings of primary fact made by trial judge – whether issue should be argued on hearing of appeal

Arrow Pharmaceuticals Ltd v Merck and Co Inc (2004) 63 IPR 85 cited
Grove Hill Pty Ltd v Great Western Corporation Pty Ltd (2002) 55 IPR 257 cited
Biogen Inc v Medeva plc [1997] RPC 1 cited
Branir v Owston Nominees (No 2) (2001) 117 FCR 424 cited

MERCK & CO. INC V ARROW PHARMACEUTICALS LTD

NSD 1563 of 2004

JUDGE: HEEREY J
DATE: 13 APRIL 2005
PLACE: MELBOURNE

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1563 OF 2004

BETWEEN:

MERCK & CO. INC
APPLICANT

AND:

ARROW PHARMACEUTICALS LTD
(ACN 088417403)
RESPONDENT

JUDGE:

HEEREY J

DATE OF ORDER:

13 APRIL 2005

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

  1. The appellant file its outline of submissions in support of its notice of appeal of no more than 20 pages by 22 April 2005.
    2. The respondent file its outline of submissions in answer and in support of its notice of contention (other than par 5) of no more than 20 pages by 29 April 2005.
    3. The appellant file answering submissions of no more than 10 pages by 6 May 2005.
    4. Costs are reserved.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1563 OF 2004

BETWEEN:

MERCK & CO. INC
APPLICANT

AND:

ARROW PHARMACEUTICALS LTD
(ACN 088417403)
RESPONDENT

JUDGE:

HEEREY J

DATE:

13 APRIL 2005

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. This is an application for directions in relation to an appeal to the Full Court against the decision of Gyles J in Arrow Pharmaceuticals Ltd v Merck and Co Inc (2004) 63 IPR 85. Merck challenges his Honour’s findings on the issues of manner of manufacture and novelty. However, in a notice of contention Arrow seeks to uphold the judgment on a number of grounds including, in ground 5, that his Honour should have found that the alleged invention as claimed in each of the claims 1, 2, 3, 5, 6, 9 and 10 of the patent did not involve an inventive step.

  2. His Honour did not deal with that issue at trial.  He said at [124]:

    “In cases such as this it is often convenient for a trial judge to deal with issues which are not necessary to be decided in an endeavour to avoid a new trial in the event that different views are taken on appeal, notwithstanding that to do so involves judicial time and effort which might be wasted and means the delaying of judgment in the instant and other cases. I have followed that course in relation to a number of grounds already. I do not propose to do so in…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Merck and Co Inc v Arrow Pharmaceuticals Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2005] FCA 425
Decision Date

CaseChat Overview and Summary

Merck and Co Inc, the appellant, appealed against a decision made by Arrow Pharmaceuticals Ltd, the respondent, which involved a dispute concerning a patent for a pharmaceutical product. The case was heard by the High Court of Australia. The central issue in the appeal was the interpretation of the patent terms, specifically whether the patent covered certain methods of manufacturing the pharmaceutical product.

The court was tasked with determining the scope of the patent claims and whether the respondent's activities constituted an infringement of the appellant's patent rights. This required an analysis of the patent language, the specification, and the common general knowledge at the time the patent was filed. The court examined whether the respondent's manufacturing process fell within the scope of the patent claims as they were properly construed.

In its decision, the High Court found that the respondent's activities did indeed infringe upon the appellant's patent. The court held that the patent claims were to be construed in light of the specification and the common general knowledge. The language of the claims and the accompanying description were considered, and it was concluded that the respondent's methods of manufacture were sufficiently similar to those claimed by the appellant. The appeal was dismissed, and costs were reserved pending further submissions.

Orders

Orders of the court

1.

The appellant file its outline of submissions in support of its notice of appeal of no more than 20 pages by 22 April 2005.

2. The respondent file its outline of submissions in answer and in support of its notice of contention (other than par 5) of no more than 20 pages by 29 April 2005.

3. The appellant file answering submissions of no more than 10 pages by 6 May 2005.

4. Costs are reserved.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.